Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Galcanezumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Galcanezumab. Displaying page 1 of 1.
    EudraCT Number: 2021-006176-16 Sponsor Protocol Number: I5Q-NS-O001 Start Date*: 2022-09-26
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT)
    Medical condition: High-frequency episodic migraine.
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004852 10082019 Episodic migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004622-28 Sponsor Protocol Number: I5Q-MC-CGAT Start Date*: 2021-02-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study
    Medical condition: Chronic Migraine
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066636 Chronic migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Completed) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005234-21 Sponsor Protocol Number: I5Q-MC-CGAR Start Date*: 2016-10-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache
    Medical condition: Episodic Cluster Headache, Chronic Cluster Headache
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10059133 Cluster headache PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FI (Completed) ES (Completed) DK (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000600-42 Sponsor Protocol Number: I5Q-MC-CGAW Start Date*: 2018-06-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults with Treatment-Resistant Migraine - The CONQUER Study
    Medical condition: Treatment-resistant Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed) HU (Completed) DK (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004351-23 Sponsor Protocol Number: I5Q-MC-CGAS Start Date*: 2021-02-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study
    Medical condition: Episodic Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027602 Migraine headache LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Completed) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001884-38 Sponsor Protocol Number: I5Q-MC-CGAJ Start Date*: 2015-12-07
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients with Migraine.
    Medical condition: Episodic or chronic migraine headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005429-11 Sponsor Protocol Number: I5Q-MC-CGAM Start Date*: 2015-07-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache
    Medical condition: Chronic Cluster Headache
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10009698 Cluster headaches LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) DK (Completed) FI (Completed) BE (Completed) FR (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000149-22 Sponsor Protocol Number: I5Q-MC-CGAL Start Date*: 2015-07-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10009698 Cluster headaches LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) DK (Completed) BE (Completed) FI (Completed) ES (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001883-21 Sponsor Protocol Number: I5Q-MC-CGAI Start Date*: 2016-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study
    Medical condition: Chronic Migraine Headache
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001882-17 Sponsor Protocol Number: I5Q-MC-CGAH Start Date*: 2016-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Migraine - the EVOLVE-2 Study
    Medical condition: Episodic Migraine Headache
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 15:46:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA